# Managed Care Under Pressure - Week of June 6, 2026: Medicaid Payment-Cap Rule Lands

> Managed care newsletter for the week of May 30 to June 6, 2026. A new CMS rule caps Medicaid state-directed and supplemental payments at 100% to 110% of Medicare by 2029, and PBM reform crossed from theme into signed legislation, while operator guidance stayed off tape.


## Managed Care Under Pressure

### Week of May 30 – June 6, 2026: Medicaid payment-cap rule lands

---

```request-access
variant: ghost
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## TL;DR

- **Policy tape, not operator tape.** This week's managed-care signal came from the policy side, a policy analyst's read, a generalist investor show, and a CVS-sponsored episode, rather than from the operators or the sell side. The names themselves stayed quiet; the rule changes did not.
- **The one thing that moves numbers:** a new CMS rule capping Medicaid state-directed and supplemental payments at **100% of Medicare rates (expansion states) and 110% (non-expansion) by 2029**, described as "effectively cutting payments roughly in half" versus current commercial-rate benchmarks. Negative read-through to Medicaid MCO rate adequacy (CNC, MOH, ELV) and to hospital partners (HCA) who book state-directed payments as revenue.
- **"The end of PBMs as they were created"** is now the recurring frame: Tennessee's FAIR-RX Act, a mirror federal bill, the FTC's CVS findings, and GLP-1s routing around the wholesale channel. Live overhang for CVS (Caremark) and CI (Express Scripts); structurally relevant to UNH (Optum Rx).

## What's new

Ranked by what is actionable for the book.

**1. Medicaid state-directed payment caps, the most concrete negative this week.** On *Health:Further*, policy analyst Emily Evans detailed a CMS/White House rule, released the day after Senator Cassidy lost his primary (week of roughly May 20), capping state-directed and supplemental payments at **100% of Medicare for expansion states and 110% for non-expansion states by 2029** ([Health:Further, ep. 192, 2026-05-30](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgQFHgYCffzqvVS49vkoQYaUocj-2BG3JMJuOXugJmiT-2FV2ngqA8lsjxC03Qhu0kUixSHH1MJq31LITifZVpo5X2pJT4yydzKnNlOQVziwR48VQ-3D-3DgUds_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXW-2BtmsxAdFj83Aq3dSOtNR-2FrKbKODFb-2BU91-2BOwrBehR4ySSoBvEyFq6hsW29YIEm6xbrIsUDeGP9zBxQ3sJs4c5HYzzQDUALUM3W5zUx1jBQJoGmjBQw2hWlGgsDPvp8MeLjflLk3TF8ptx5aIkGqKZ-2FVOlLeHOnNaLGCVviGkhg-3D-3D)). Evans framed the mechanism plainly: plans agree to be taxed, the state raises revenue, a roughly 1:1 federal match flows back through MCOs to hospitals and nursing homes; the federal share of Medicaid has risen from roughly 50% in the 1990s to 70% to 80% today. She noted HCA's revenue per Medicaid admission "hockey sticks" on state-directed payments, quantifying the provider-side exposure. *Why it matters:* this is incremental to the "one big, beautiful bill" (which hit the managed-care and state-directed side); the new rule additionally squeezes fee-for-service supplemental payments. It pressures the funding plumbing under Medicaid MCO rate adequacy with a hard 2029 phase-in.

**2. PBM model unwind hardens from theme to legislation.** Same episode: Evans flagged Tennessee's signed **FAIR-RX Act** (illegal for one company to own both a PBM and a pharmacy in-state), a **bipartisan federal mirror bill** now introduced, and the FTC finding that CVS's PBM paid independent pharmacies less than its own retail pharmacies for the same drugs ([Health:Further, 2026-05-30](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgQFHgYCffzqvVS49vkoQYaUocj-2BG3JMJuOXugJmiT-2FV2ngqA8lsjxC03Qhu0kUixSHH1MJq31LITifZVpo5X2pJT4yydzKnNlOQVziwR48VQ-3D-3DPSdr_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXW-2BtmsxAdFj83Aq3dSOtNR-2FrKbKODFb-2BU91-2BOwrBehR8VI0Cghmuphw-2BK8bwMNyNHbviPM3qcM1Q8i6eCxULAA-2BlWgTFdd-2FoRfoK2m-2BFFVAOs7UeFd473bVXOp-2FGhberUmhXMQn3u-2F9Od4FSNebvyEfOVEn6P7tvnSW8CqLYZLdw-3D-3D)). Her call: *"I think we are looking at the end of PBMs as they were originally created,"* citing UNH moving to fixed fees, CI having already sold its PBM, and CVS as "the last big one." *Why it matters:* keeps regulatory tail risk live on Caremark (CVS) and Express Scripts (CI) economics into the election-season legislative calendar.

**3. CVS Caremark's own defense, operator voice, but sponsored.** On a CVS-sponsored *A Health Podyssey* episode, James Marjota, Chief Growth Officer at CVS Caremark, argued pharmacy benefits are now "more than 50% of the cost that typical plan sponsors are spending," that specialty is "close to 50% of the cost... but only 2-3% of members," and claimed "over 90% adoption and conversion to the biosimilar" (context: adalimumab) "saving our customers $1.8 billion plus" ([A Health Podyssey, 2026-06-03](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOheIc-2BHHcHPtpCUGG9vi7CflB1Q665nHn3Ka6MzvwNUfLYFrSD0jh4Rm8BNxBN38NV5n1Jze3hA4jZojBmfehGBiI1CPatt5jrgfZDZrBXWHA-3D-3DD7IA_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXW-2BtmsxAdFj83Aq3dSOtNR-2FrKbKODFb-2BU91-2BOwrBehRyDB0zg1YBsSacA-2FGVQpSGIyy3R38BoEY3mHFpNpgd-2FCYXYVoKDI8xcNFB0jRd3hDiqJYWbY8XvGnnBqi5bLrW8GExnQWp-2BFbNY1AvvHH9h3NGSC2HZo1OBhx-2F5HG73EFg-3D-3D)). *Why it matters:* it is the only operator voice on tape, but it is paid placement with no adversarial counter, no Aetna MLR, no strategic-review detail. Treat as promotional, not as a guidance datapoint.

**4. UNH vertical-integration and DOJ framing resurfaces (pundit).** On *Telltales*, generalist investor-hosts argued UNH's vertical integration could be "the largest antitrust case of all time" and that AI is being used to "game the medical coding system... to get the maximum reimbursement for Medicare" ([Telltales, 2026-06-03](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOia8DH7mFByxAR-2Bw4zVpA3snKUEQLLHj1NbthqPDcHJOqNSulDp4eZTcimr2rHe2h-2B2zQVZ8SlCd9BRSjuTUSw3EnOxfnrIzDwSqZpwINZROQ-3D-3DwALq_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXW-2BtmsxAdFj83Aq3dSOtNR-2FrKbKODFb-2BU91-2BOwrBehR-2Bt2lVk-2Bkj2zWG3t-2BD7MdbtcWV3C9QsoQgG-2Bk6GGj9080YsMxV791f85Pfv1QmSDWNpTjGsFIyWA-2FGZLnlCHOu1GVrwhfvDqBzGN3MijMH7yHTgzfCEuAhSY0BSiE4nCQw-3D-3D)). *Why it matters:* it keeps the DOJ MA-coding overhang in the narrative, but these are pundits, not sector specialists, and UNH is referenced only in passing. Sentiment, not signal.

**5. GLP-1s routing around the channel.** Evans noted GLP-1s now available "for free or near almost nothing" vs. "$1,300 a few months ago," with Hims, Lilly Direct, GoodRx, and Amazon One Medical selling "outside of PBMs, outside of this wholesale channel" ([Health:Further, 2026-05-30](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgQFHgYCffzqvVS49vkoQYaUocj-2BG3JMJuOXugJmiT-2FV2ngqA8lsjxC03Qhu0kUixSHH1MJq31LITifZVpo5X2pJT4yydzKnNlOQVziwR48VQ-3D-3De7YT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXW-2BtmsxAdFj83Aq3dSOtNR-2FrKbKODFb-2BU91-2BOwrBehR-2F6Q0g4eH-2BefklrlnKrx6NoqBDdQ-2FIVV98YJm5-2BSTVLD3T4bgtT1j2adGn6MuNhD-2B3-2FhCaPX-2BbMUxvMDV-2Fn2CP4qG6EuaExBLNOryXLODJXe9Af2CxTydc3cvHDMs-2Bh40Q-3D-3D)). *Why it matters:* cuts two ways. Direct-to-consumer disintermediation pressures PBM rebate economics, but falling net GLP-1 prices ease the MLR cost-trend math if utilization migrates off the medical and pharmacy benefit.

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## The debate

**Bull, utilization and MA funding have bottomed.** Q1'26 absorbed the worst of post-pandemic normalization plus V28 Year 2; 2027 bids are filed into a more constructive CMS benchmark posture; the 2026 AEP cuts pruned unprofitable membership; Star settlements crystallize the QBP backstop. On this view FY26 EPS is the trough and you are paid to own the names through the next bid cycle. *Nothing on tape this week added to the bull ledger.*

**Bear, structurally higher trend plus a hostile policy and legal backdrop.** This week fed the bear: the Medicaid payment-cap rule is a fresh, datable funding squeeze with a 2029 cliff; PBM reform moved from theme to signed law plus a federal bill; the DOJ and coding narrative persists. Layer that on structurally higher trend (GLP-1, behavioral, outpatient migration), V28's FY27 bite, RADV cash recoveries, and the enhanced-ACA-subsidy cliff, and the bear case is that valuations need a numbers reset, not a sum-of-the-parts rerate.

> The pull-quote of the week, from a policy analyst, not an operator: *"I think we are looking at the end of PBMs as they were originally created."*

## Stocks in play

**UNH**: *Bull:* Optum Health margin recovery into FY27, RADV/DOJ tail priced in. *Bear:* DOJ MA-coding overhang (kept alive on tape this week, pundit-level), V28, Star reset risk; Optum Rx caught in the PBM-model unwind. *Next catalyst:* Q2'26 print (MLR vs. guide, FY26 EPS reiteration), DOJ procedural updates.

**CVS**: *Bull:* Aetna MA repricing into 2027, Caremark scale, strategic-review optionality. *Bear:* PBM reform now legislative (FAIR-RX plus federal mirror bill, FTC findings), 340B litigation ($250M hospital suit alleged), MA membership still mispriced. *Next catalyst:* Q2'26 Aetna MLR, strategic-review disclosure, PBM legislative calendar.

**HUM**: *Bull:* cleanest 2027 MA bid leverage. *Bear:* highest beta to MA funding and trend; Medicaid sale execution. *Next catalyst:* Q2'26 MLR, 2027 bid color. *No podcast signal this week.*

**ELV**: *Bull:* Carelon services growth offsetting MA pressure. *Bear:* Medicaid acuity now layered with the state-directed payment-cap rule; enhanced-subsidy cliff. *Next catalyst:* Q2'26 Medicaid/MA MLR splits, 2027 exchange filings. *No company-specific tape.*

**CNC**: *Bull:* Medicaid acuity reset largely behind, exchange margins resilient. *Bear:* the SDP cap rule pressures the Medicaid rate floor into 2029; enhanced-subsidy expiration. *Next catalyst:* Q2'26 HBR by segment, state rate updates. *Read-through only, not named on tape.*

**MOH**: *Bull:* disciplined Medicaid underwriting, contract wins. *Bear:* most Medicaid-levered to the SDP cap dynamic; state rate timing. *Next catalyst:* Q2'26 MCR, RFP wins and losses. *Read-through only.*

**CI**: *Bull:* Evernorth growth, MA exit removed drag. *Bear:* Express Scripts squarely in the "end of PBMs" frame. *Next catalyst:* Q2'26 Evernorth growth, PBM legislative calendar.

## Read-throughs

- **Medicaid/exchange (CNC, MOH, ELV):** the SDP and supplemental cap rule is the new, datable negative. Watch state rate filings for how quickly the 2029 caps get discounted into MCO rates, and watch hospital lobbying to reverse it ([Health:Further, 2026-05-30](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgQFHgYCffzqvVS49vkoQYaUocj-2BG3JMJuOXugJmiT-2FV2ngqA8lsjxC03Qhu0kUixSHH1MJq31LITifZVpo5X2pJT4yydzKnNlOQVziwR48VQ-3D-3DxVW7_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXW-2BtmsxAdFj83Aq3dSOtNR-2FrKbKODFb-2BU91-2BOwrBehR12uHjV0gcA0boc1uLE8t6lMexDDn19POHagmlvrB1mWpaOyANjh1J-2B3FaFU2sbSGxHQCEyTcRHwT5Wr6XKwvSQ0aHpj-2B023xcbdYkWni7DFC9VR5DAvVoZ6ZtW-2BCX6ukw-3D-3D)). ACA out-of-pocket maximums rising roughly 30% in 2027 (to roughly $15,000 individual and roughly $31,000 family per Evans) compounds the affordability and attrition risk into the subsidy cliff.
- **PBMs and Optum-style arms (CVS, CI, UNH):** reform is now signed law in one state plus a federal mirror bill; the rebate model is unwinding regardless of legislation ([Health:Further, 2026-05-30](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgQFHgYCffzqvVS49vkoQYaUocj-2BG3JMJuOXugJmiT-2FV2ngqA8lsjxC03Qhu0kUixSHH1MJq31LITifZVpo5X2pJT4yydzKnNlOQVziwR48VQ-3D-3DUXhn_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXW-2BtmsxAdFj83Aq3dSOtNR-2FrKbKODFb-2BU91-2BOwrBehRzGbsCLa-2F6g3u8nwaUdBM28vh7ArxhWaM5qnoIQ3AUTFvFSyQVdSiV434nC7-2FUirJlMgWc6X-2Fw3H-2B9MT3nJm5V3mtuhMdjsuuWeQEaAMuh2eyrSr4QC9-2FXiXfgaWY3t31g-3D-3D)). CVS's own operator defense ([A Health Podyssey, 2026-06-03](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOheIc-2BHHcHPtpCUGG9vi7CflB1Q665nHn3Ka6MzvwNUfLYFrSD0jh4Rm8BNxBN38NV5n1Jze3hA4jZojBmfehGBiI1CPatt5jrgfZDZrBXWHA-3D-3DfK-v_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXW-2BtmsxAdFj83Aq3dSOtNR-2FrKbKODFb-2BU91-2BOwrBehR1870PTZYAGzA6mO7Hu-2Fm0BlywZaH1as7iaHyF3aM1iMhzJ-2BZYp8zB7x0ztib0hill-2BHKGD95j8JxCTWybXLI4mEeuCa-2FYgYmsaKLHLstuvfMNTpYBBkS0K91qiz2ANbkg-3D-3D)) is the rebuttal, but sponsored.
- **Hospitals and providers:** the mirror trade is live. The SDP cap is a direct hit to provider Medicaid revenue (HCA's per-admission revenue "hockey sticks" on these payments), the offsetting risk to a long-facilities and short-payers framing.
- **GLP-1 cost exposure:** falling net prices and DTC channels ([Health:Further, 2026-05-30](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgQFHgYCffzqvVS49vkoQYaUocj-2BG3JMJuOXugJmiT-2FV2ngqA8lsjxC03Qhu0kUixSHH1MJq31LITifZVpo5X2pJT4yydzKnNlOQVziwR48VQ-3D-3DCkE1_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXW-2BtmsxAdFj83Aq3dSOtNR-2FrKbKODFb-2BU91-2BOwrBehR-2BBD5AX9i6Nv5wIwVvJJiYcj3NCYPxQ9J3vAxJ6BYqkFi2dkmFkYZAxFeWXKdhJqBdufPyOqsiF4LQyz44NJZXeJtN76vjJZQevlpqdiVvnZZipYFZ-2BIAcffsGLrLY-2BN6w-3D-3D)) are a mixed read. Eases MLR cost-trend if utilization migrates off-benefit, pressures PBM rebate capture.

## What changed vs last week

Last week (May 23–30) was a fully quiet tape, zero citations. **This week the policy channel woke up.** The incremental items versus last week's standing setup: (1) a concrete, datable Medicaid state-directed and supplemental payment-cap rule (100% to 110% of Medicare by 2029) that did not exist on tape last week; (2) PBM reform crossing from theme into signed legislation (Tennessee FAIR-RX) plus a federal bill; (3) the CVS 340B hospital litigation ($250M alleged) surfacing. What did **not** change: still no operator guidance, no sell-side or buy-side MCO commentary, and no tape on the 2027 MA Rate Notice, V28, RADV, Star ratings litigation, MA enrollment and benefit cuts, or HUM/ELV/CNC/MOH company-specifics. The MA-funding-versus-trend debate going into Q2'26 prints remains the core argument; this week added to the Medicaid and PBM legs, not the MA leg.

```request-access
variant: banner
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```